Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(5):329-331; doi:10.1093/jnci/94.5.329
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fintor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fintor, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 5, 329-331, March 6, 2002
© 2002 Oxford University Press

NEWS

Direct-to-Consumer Marketing: How Has It Fared?

Lou Fintor

Although the United States and New Zealand are the only two countries permitting direct-to-consumer (DTC) advertising of pharmaceuticals, many other countries are taking a close look at their policies to see what will best meet the needs of consumers.

"A growing number of patients want to be empowered; they are demanding more information. We now have a situation where advertising lets patients know about potential new medicines so they have more knowledge about treatment choices when they sit down to discuss options with their physicians," said Jeff Trewhitt, spokesperson for the Pharmaceutical Research and Manufacturers Association of America (PhRMA), a Washington, D.C.-based national trade association of pharmaceutical and biotechnology firms.

In 1997 the U.S. Food and Drug Administration issued a regulatory "clarification" allowing DTC advertising; an explosion of television, radio, and print drug promotional advertisements followed (see News, June 21, 2000, p. 964).

The FDA requires all advertisements to . . . [Full Text of this Article]

Regulatory Boondoggle?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. A. Abel, S. J. Lee, and J. C. Weeks
Direct-to-Consumer Advertising in Oncology: A Content Analysis of Print Media
J. Clin. Oncol., April 1, 2007; 25(10): 1267 - 1271.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Jagsi
Conflicts of Interest and the Physician-Patient Relationship in the Era of Direct-to-Patient Advertising
J. Clin. Oncol., March 1, 2007; 25(7): 902 - 905.
[Full Text] [PDF]

Home page
 The OncologistHome page
G. A. Abel, R. T. Penson, S. Joffe, L. Schapira, B. A. Chabner, and T. J. Lynch Jr.
Direct-to-Consumer Advertising in Oncology.
Oncologist, February 1, 2006; 11(2): 217 - 226.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gray and O. I. Olopade
Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware
J. Clin. Oncol., September 1, 2003; 21(17): 3191 - 3193.
[Full Text] [PDF]